Watch Dr. Chang explain the role of dysbiosis in the pathophysiology of IBS-D

Christopher Chang, MD, PhD

Gastroenterology Specialist at the University of New Mexico School of Medicine Renowned expert in GI motility and microbiome research Honors from the University of California, San Francisco School of Medicine 1995

Dr. Chang’s extensive research has focused on understanding how the GI microbiome can affect health and lead to disease. In this video, watch Dr. Chang explain the role of dysbiosis in the pathophysiology of IBS-D.


XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.